anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Patients undergoing carotid endarterectomy (CEA) have a high restenosis rate, which increases the risk of stroke, and there is still a lack of effective treatment for restenosis. The cause of stenosis is related to local inflammatory reactions. Some basic studies have shown that the inflammatory response causing arterial stenosis is closely related to the nerve axons distributed in its outer membrane, and that removal of the nerve is effective in reducing the inflammatory response to prevent arterial stenosis. Therefore, we propose to design a randomized controlled trial to study whether disconnecting the carotid sinus nerve during a CEA operation can reduce carotid arterial restenosis.
METHOD/DESIGN: This study is a randomized, double-blind, single-center study. We will recruit 276 patients, who will be randomly divided into the experimental group and the control group. Based on the standard CEA operation, the operator will search for the carotid sinus nerve on the surface of the internal carotid artery and will entirely transect it in the experimental group. Both groups will be guided with the same postoperative treatment and will be followed up every 3 months for 3 years after the operation. The main indices observed will be the carotid restenosis rate, incidence and nature of carotid plaque, and carotid blood flow velocity. Other indices will be arrhythmia, blood pressure variability, and biomarkers of atherosclerosis, such as blood lipids, hypersensitive C-reactive protein (hs-CRP), homocysteine, and total bilirubin.
DISCUSSION: It is expected that carotid sinus nerve transection will significantly reduce the occurrence of restenosis after CEA, decrease the incidence of ischemic stroke, and realize the effective primary prevention of stroke.
TRIAL REGISTRATION: ChiCTR2300073652. Registered on July 18, 2023.
Pts get a PET/CT study with approx.150-200 MBq of 68Ga-DOTA-JR11. Lesions with focal radiotracer uptake not explained by physiologic sstr2 expression will be interpreted as metastatic disease. If 68Ga-DOTA-JR11 uptake by metastases with a diameter of more than 2 cm is less than the physiologic radiotracer uptake by the liver, no further imaging \& therapy will be performed as part of the study, as it is unlikely that pts with this low radiotracer uptake will benefit from PRRT (2). All other pts will undergo a dosimetric study with 1850 MBq (less than 100 μg peptide) of 177Lu-DOTA-JR11. Results of the dosimetry study, will determine the balance of activity of 177Lu-DOTA-JR11 that can be administered without exceeding the radiation dose limits. This activity will be split into 2 equal amounts to be delivered in 2 cycles, approximately 3 months apart. After each therapy cycle, pts will be followed clinically for 3 months.
Participants with R/R FL will receive obinutuzumab 400 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m\^2/day and cyclophosphamide 250 mg/m\^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
Chimeric antigen receptor (CAR)-immune cell therapy has revolutionized the anti-tumor field, achieving efficient and precise tumor clearance by directly guiding immune cell activity to target tumors. In addition, the use of CAR-immune cells to influence the composition and function of the immune system and ultimately achieve virus clearance and immune system homeostasis has attracted the interest of researchers. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered a global pandemic of coronavirus disease 2019 (COVID-19). To date, the rapidly mutating SARS-CoV-2 continues to challenge existing therapies and has raised public concerns regarding reinfection. In patients with COVID-19, the interaction of SARS-CoV-2 with the immune system influences the course of the disease, and the coexistence of over-activated immune system components, such as macrophages, and severely compromised immune system components, such as natural killer cells, reveals a dysregulated immune system. Dysregulated immune-induced inflammation may impair viral clearance and T-cell responses, causing cytokine storms and ultimately leading to patient death. Here, we summarize the research progress on the use of CAR-immune cells against SARS-CoV-2 infection. Furthermore, we discuss the feasibility, challenges and prospect of CAR-immune cells as a new immune candidate therapy against SARS-CoV-2.
PURPOSE: To provide a method for storing blood, capable of preventing blood coagulation reaction by blending blood with a specific substance so as to become isotonic state and carrying out long-term stabilization of blood cell and enabling longer time storage of blood. CONSTITUTION: (A) One substance selected from a disaccharide (e.g. maltose), a trisaccharide (e.g. maltotrilose), a polysaccharide (e.g. maltotetraose) extruding these saccharides and a sugar alcohol (e.g. glucosylmannitol) is blended with blood so as to be isotonic and further preferably blended with (B) a phosphoric acid compound (e.g. disodium hydrogenphosphate) and (C) a serine protease inhibitor (e.g. para-aminophenylmethanesulfonyl fluoride) to store blood.
Physostigmine salicylate, 1 to 2 mg, SC or IV, reportedly will reverse symptoms of anticholinergic intoxication. * A second injection may be given after 2 hours if required. Otherwise treatment is symptomatic and supportive. Induce emesis or perform gastric lavage (contraindicated in precomatose convulsive, or psychotic states). Maintain respiration. A short-acting barbiturate may be used for CNS excitement, but with caution to avoid subsequent depression; supportive care for depression (avoid convulsant stimulants such as picrotoxin, pentylenetetrazol, or bemegride); artificial respiration for severe respiratory depression; a local miotic for mydriasis and cycloplegia; ice bags or other cold applications and alcohol sponges for hyperpyrexia, a vasopressor and fluids for circulatory collapse. Darken room for photophobia.
Patients receive standard therapy alone. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
PURPOSE:To prepare a hair restorer in large amount at a low cost, by decocting pulvis swertiae with water, adding raw garlic to the decoction, and boiling down the mixture to paste, and if necessary adding alcohol to the paste. CONSTITUTION:Pulvis swertiae (1.8 grams) is boiled in water (1,080cc) over a medium fire to reduce to about one half (540cc). Raw gralic (400 grams) is added to the decoction obtained above, and boiled down to a paste over a medium fire to obtain the objective hair restorer. The paste may be strained to remove coarse particles and mixed with 0.03% of an alcohol. The gralic and pulvis swertiae used as main components improve the function of hair, prevent hair falling, facilitate the circulation of the blood thereby increasing metabolism, increase the supply of  nutrient to the hair root cells thereby increasing the hair-growing function of the cell, and turn gray hair to black from the hair root. The agent is effective only when the function of the hair root is still active.
FIELD: amino acids, pharmacy. SUBSTANCE: invention relates to the improved method of synthesis of gamma-L-glutamylhistamine of the formula (I). Method involves acylation of histamine with gamma-pentafluorophenyl ester of L-glutamic acid L-tert.-butylhydroxycarbonyl--α--benzyl ester in an organic solvent followed by removal of protecting groups, hydrogenolysis, isoelectric precipitation and recrystallization. Invention relates also to the use of the compound of the formula (I) as an agent showing an antioxidant, antiradical, lipid-regulating, hypoglycaemic, antiasthmatic, hepatoprotective, antiviral, antibacterial, antitumor, antimetastatic, adaptogenic effect and capability to modulate metabolism of arachidonic acid and other therapeutic effects. Invention relates to also a pharmaceutical composition showing the above indicated properties that includes an active component - the compound of the formula (I) taken at the effective amount and special additions. EFFECT: improved method of synthesis, valuable curative properties. 4 cl, 14 tbl, 13 ex
Patients receive steroid therapy at the discretion of the treating physician. Beginning within 3 days of starting steroids, patients receive leflunomide PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Patients who respond to leflunomide treatment will be tapered off from day 29 until day 56.
The invention discloses a skin cream with strengthened microelements, in particular to the cream which is added with snake, bee, traditional Chinese medicine, microelements supplements and the like, when an emulsion substrate is prepared. The cream has high content and complete sorts of macroelements including calcium, phosphor, kalium, sodium and magnesium; the microelements include zinc, copper, ferrum, manganese, selenium and the like and also contain protein, fatty acid, amino acid, cholesterol, vitamin, hormone, various kinds of enzymes, auxin, flavone, aromatic substances, etc. Various nutrient active components take an important role in regulating life activity. Skin is the largest organ of human body and is concerned with the excretion and the metabolism of human body. The contents of zinc, copper, ferrum and selenium are most abundant. Various diseases including skin disease of human body are caused by the insufficiency or the excessive amount of elements in vivo. The skin disease is always treated by chemical medicine or hormone, thereby resulting in that various skin diseases become obstinate diseases which can hardly be cured clinically. The skin cream uses the natural microelements in animals and plants to penetrate and be absorbed by the skin, so as to complement and regulate the element balance in vivo continuously to remedy and prevent various kinds of skin diseases with surprisingly unique effect.
OBJECTIVE: Semantic tool knowledge underlies the ability to perform activities of daily living. Models of apraxia have emphasized the role of functional knowledge about the action performed with tools (e.g., a hammer and a mallet allow a "hammering" action), and contextual knowledge informing individuals about where to find tools in the social space (e.g., a hammer and a mallet can be found in a workshop). The goal of this study was to test whether contextual or functional knowledge, would be central in the organization of tool knowledge. It was assumed that contextual knowledge would be more salient than functional knowledge for healthy controls and that patients with dementia would show impaired contextual knowledge.
METHODS: We created an original, open-ended categorization task with ambiguity, in which the same familiar tools could be matched on either contextual or functional criteria.
RESULTS: In our findings, healthy controls prioritized a contextual, over a functional criterion. Patients with dementia had normal visual categorization skills (as demonstrated by an original picture categorization task), yet they made less contextual, but more functional associations than healthy controls.
CONCLUSION: The findings support a dissociation between functional knowledge ("what for") on the one hand, and contextual knowledge ("where") on the other hand. While functional knowledge may be distributed across semantic and action-related factors, contextual knowledge may actually be the name of higher-order social norms applied to tool knowledge. These findings may encourage researchers to test both functional and contextual knowledge to diagnose semantic deficits and to use open-ended categorization tests.
Thyroid cancer is the most common endocrine malignancy, with a female predominance. Thyroidectomy is the main treatment for thyroid cancer, and considering the good prognosis of thyroid cancer, endoscopic thyroid surgery, which avoids neck incision, is being widely used in the clinic in order to improve the life treatment of patients. Among them, endoscopic thyroidectomy with transoral approach has a shorter learning curve because of the short surgical path. However, due to the complex structure of the neck, small space, and rich blood supply of the thyroid gland, surrounded by parathyroid glands and important nerves, endoscopic thyroid is difficult and has a long learning curve. In addition, a series of complications such as haemorrhage, hypoparathyroidism and laryngeal reentrant nerve injury can seriously affect the quality of patient survival. Difficult thyroidectomy is usually characterized by a long operative time, high intraoperative bleeding and a high incidence of postoperative complications. According to the literature, in open thyroid surgery, the degree of difficulty is associated with factors such as goiter, inflammation, and hyperthyroidism. However, the degree of difficulty of thyroidectomy due to various factors varies and is difficult to predict. Surgical difficulty is closely related to the outcome and safety of thyroidectomy, which is an urgent concern for surgeons. And there is no study on the degree of difficulty of transoral and submental endoscopic thyroidectomy, therefore, there is an urgent need for an effective and objective method to determine the preoperative factors affecting the degree of surgical difficulty and to establish a model for validation, so that it can be subsequently replicated in other hospitals.
The term frailty denotes a multi-dimensional syndrome characterized by increased vulnerability and decreased physiologic reserves. Frailty stratification predicts a patient's risk of death and need for institutional care. The construct is well validated, but there is not one single accepted operational definition. The CSHA Clinical Frailty Scale (CFS) is a 7-point scale relying on clinical judgement. It is a global clinical measure of biological age, and it mixes co-morbidity, disability and cognitive impairment.Though frailty instruments so far mainly have been used in a geriatric context, it has been pointed out as relevant for cardiologic patients as well, e.g. regarding risk stratification for elderly patients with NSTEMI. The purpose of this study is to describe patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI) especially regarding the following variables: cardiovascular risk, co-morbidity and frailty. The investigators hypothesize that the degree of frailty influences the benefit from coronary angiography and the possible invasive treatment which can follow.
BACKGROUND: Upper arm aesthetics often suffer from aging effects such as skin laxity and sagging due to collagen and elastin depletion. Fat loss, obesity, and weight fluctuations further exacerbate these issues. Existing classification systems for upper arm excess are complex and have practical limitations.
OBJECTIVES: The aim of this study was to develop a more concise and clearer classification of upper arm excess that can guide surgical interventions effectively and assess clinical outcomes.
METHODS: Patients undergoing upper arm rejuvenation surgery from January 2020 to January 2023 were categorized as mild, moderate, or severe. Mild cases underwent suction-assisted liposuction (SAL), moderate cases underwent radiofrequency-assisted liposuction combined with SAL, and severe cases underwent brachioplasty combined with SAL. Arm circumferences and BODY-Q questionnaires were collected pre- and postoperatively.
RESULTS: The study included 50 female patients, aged 21 to 49 years. The average follow-up time was 7.5 [2.2] months. Arm circumference reduction rates were 6.8% in mild cases, 15.1% in moderate cases, and 17.3% in severe cases. Regarding the BODY-Q questionnaire for upper arms, the average score increased by 0.9 for mild, 2.1 for moderate, and 2.9 for severe cases. Complications were minimal, including 1 seroma and 2 cases of scar widening.
CONCLUSIONS: The revised classification system for upper arm excess proved effective in guiding surgical decisions. Selecting the surgical approach based on severity resulted in satisfactory outcomes based on BODY-Q scores. This system offers a concise, objective, and practical tool for plastic surgeons.
The present invention relates to a health eye shade and a medicine for the eye shade. The eye shade comprises an eye shielding shad and a binding strap and is characterized in that an interlayer is arranged on the inner side of the eye shielding shade, and the inner side of the interlayer is made of reticular fabric. A medicine bag containing medicines is arranged in the interlayer, and the medicines comprise the components by the weight proportion: 4 to 5 portions of safflower, 2 to 4 portions of ground beeltle, 2 to 4 portions of scorpion and 1 to 2 portions of dragon blood. The present invention adopts traditional Chinese medicine, and the medicine is applied to penetrate skins. Particularly, the eye shade is suitable for being used during a sleep so that the medicine acts for a long time. Consequently, the eye shade has a good effect and particularly has a good therapeutic effect on myopia, hyperopia, astigmia, presbyopia, etc. which are caused by ametropia.
The subject invention pertains to cocrystals of dexamethasone (DEX) and a benzenediol cocrystal composed of a 1:1 molar ratio of DEX and the benzenediol. The benzenediol can be catechol (CAT) or resorcinol (RES). The DEX and benzenediol cocrystal are formed by grinding crystalline DEX where the crystalline benzenediol are combined in the 1:1 molar ratio. Grinding can be performed at room temperature. Cocrystals can be thermally annealed or exposed to humidity to enhance cocrystal formation. The DEX−CAT or DEX-RES cocrystals can be included in a medicament for use in treatments for allergies, asthma, rhinitis, cancer, diabetes, anemia, ulcers, and viral infections. The DEX−benzenediol cocrystal can be sieved to provide particles that are in the range of 10 to 45 μm that can be used for intranasal administration with improved dissolution performance.
Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants undergo PET/CT scan over 60 minutes.
AIMS: The underlying biological mechanisms of ventricular fibrillation (VF) during acute myocardial infarction are largely unknown. To our knowledge, this is the first proteomic study for this trait, with the aim to identify and characterize proteins that are associated with VF during first ST-elevation myocardial infarction (STEMI).
METHODS AND RESULTS: We included 230 participants from a Danish ongoing case-control study on patients with first STEMI with VF (case, n = 110) and without VF (control, n = 120) before guided catheter insertion for primary percutaneous coronary intervention. The plasma proteome was investigated using mass spectrometry-based proteomics on plasma samples collected within 24 h of symptom onset, and one patient was excluded in quality control. In 229 STEMI patients {72% men, median age 62 years [interquartile range (IQR): 54-70]}, a median of 257 proteins (IQR: 244-281) were quantified per patient. A total of 26 proteins were associated with VF; these proteins were involved in several biological processes including blood coagulation, haemostasis, and immunity. After correcting for multiple testing, two up-regulated proteins remained significantly associated with VF, actin beta-like 2 [ACTBL2, fold change (FC) 2.25, P < 0.001, q = 0.023], and coagulation factor XIII-A (F13A1, FC 1.48, P < 0.001, q = 0.023). None of the proteins were correlated with anterior infarct location.
CONCLUSION: Ventricular fibrillation due to first STEMI was significantly associated with two up-regulated proteins (ACTBL2 and F13A1), suggesting that they may represent novel underlying molecular VF mechanisms. Further research is needed to determine whether these proteins are predictive biomarkers or acute phase response proteins to VF during acute ischaemia.
Data from Specific Aim 1 will be used to test the following hypotheses: H1a. The body-powered prosthetic devices are embodied more than passive and myoelectric prosthetic devices. H1b. Passive cosmetic devices are embodied less than actuated cosmetic devices (agency). H1c. Body-powered terminal devices are embodied less than myoelectric terminal devices (agency).
Neonates born with gestational week \< 32 weeks, gestational week 32-37 and at term. Will will include 20-30 of each sex in each group.
Subjects randomised to FIASP and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using FIASP + closed loop intervention for 24 hours. Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
PURPOSE:The titled composition obtained by incorporating a cephalosporin compound with sucrose ester of a fatty acid. CONSTITUTION:An oral cephalosporin composition, obtained by incorporating a cephalosporin compound expressed by the formula (R is 5--6-membered heterocyclic ring containing S, etc.; R1 is 1-6C straight chain alkyl, 3-6C branched alkyl, 2-6C alkoxyalkyl, etc.; R2 is H, Cl, CH3, OCH3, etc.; R3 is H, physiologically acceptable salt or protecting group of the carboxyl group) with sucrose ester of a fatty acid at 0.01-50wt. ratio between the cephalosporin compound and the sucrose ester of the fatty acid, and having improved oral absorbability. The above-mentioned composition can be administered by dissolving or suspending a cephalosporin based antibiotic substance and the sucrose ester of the fatty acid in water or phosphoric acid buffer solution. Furthermore, the dosage form may be granule, capsule or tablet, etc.
The invention relates to a multifunctional education robot. The robot provides a highly personalized and strong-interaction learning environment through the integrated interaction unit, the emotion analysis unit, the personalized learning engine and the simulated social scene library. The interaction unit performs simulation of a social scene, interacts with the child in combination with audio, visual cues and touch feedback, and dynamically adjusts interaction interface parameters to adapt to the sensory processing characteristics of the child and minimize the risk of sensory overload. The emotion analysis unit analyzes the emotional state of the child and communicates the data to a personalized learning engine, which adjusts the social skill training program based on the information. The simulated social scene library provides matched social scenes according to instructions of the learning engine so as to promote development of social skills of children. The invention fully considers the special requirements of autism children, and aims to provide a learning platform which is strong in support, easy to accept and effectively promotes social skill development.
Patients receive pioglitazone hydrochloride PO QD for 14-42 days. Patients then undergo surgery.
Participants will receive milvexian 100 milligrams (mg) orally, twice daily and placebo that matches apixaban beginning on Day 1 through end of treatment (EOT). Participants after the EOT visit may have an option to receive open-label apixaban at the appropriate dose (5 mg or 2.5 mg, twice daily), for which the sponsor provides a 30-day supply.